Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Avonex will launch in second quarter, CEO predicts; 50-person sales force will be hired.

Executive Summary

BIOGEN's AVONEX WILL BE ON MARKET "IN THE SECOND QUARTER," Biogen CEO James Vincent predicted Jan. 9 at Hambrecht & Quist's annual conference in San Francisco. Several steps remain before approval: FDA inspection of the manufacturing facility for the multiple sclerosis therapy will be rescheduled after cancellation the week of Jan. 8 due to a blizzard; and final labeling discussions must be conducted with the agency. Avonex was unanimously recommended for approval by an FDA advisory committee in December, just four months after its NDA filing in May ("The Pink Sheet" Dec. 11, 1995, p. 5).
UsernamePublicRestriction

Register

PS027473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel